Physician profile
Kin Wing Au
NPI 1497793814
$2,512.99
in general payments reported to CMS, 2019-2025
30 companies · $76.82 in 2025
The $76.82 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $265 · 2021: $191 · 2022: $722 · 2023: $716 · 2025: $76.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $353.18 | 2020-2023 | Lynparza, Tagrisso |
| Amgen INC. | $237.07 | 2019-2022 | |
| Seagen INC. | $234.26 | 2019-2023 | Padcev, Tukysa |
| Novocure INC. | $168.60 | 2023 | Optune |
| Taiho Oncology, INC. | $166.01 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $151.27 | 2019-2023 | Keytruda, Lynparza |
| Boston Scientific Corporation | $140.64 | 2023 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Paratek Pharmaceuticals, INC. | $127.83 | 2019 | |
| Eisai INC. | $121.90 | 2023 | |
| Rigel Pharmaceuticals, INC. | $102.60 | 2022 | |
| Tempus Ai, INC | $76.82 | 2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.40 | 2019-2020 | |
| Janssen Biotech, INC. | $63.97 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.22 | 2022-2023 | Alunbrig |
| Tesaro, INC. | $45.04 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $41.83 | 2019-2022 | |
| Genzyme Corporation | $41.46 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $38.95 | 2019-2020 | |
| Emd Serono, INC. | $36.58 | 2019-2020 | |
| Visionrt, INC. | $34.86 | 2019 | |
| Amag Pharmaceuticals, INC. | $27.50 | 2019 | |
| Jazz Pharmaceuticals INC. | $25.40 | 2023 | |
| Daiichi Sankyo INC. | $25.06 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.02 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.35 | 2022 | |
| Morphosys, US INC. | $16.84 | 2022 | |
| Siemens Medical Solutions USA, INC. | $16.54 | 2021 | |
| Dova Pharmaceuticals | $16.19 | 2020 | |
| Lilly USA, LLC | $15.11 | 2019 | |
| Pharming Healthcare, INC. | $14.49 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kin Au listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.